Hepato Cellular Carcinoma Clinical Trial
— CineDoxoOfficial title:
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE: a Pilot Study
| Verified date | August 2019 |
| Source | University Hospital, Strasbourg, France |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard
treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
Clinical recommendations for cTACE indicate that the doxorubicin solution may be
reconstituted in either aqueous solution or iso-osmolar ionic iodinated contrast media. There
is no consensus on which solvent should be used. Hence, the clinical evaluation of Lipiodol
cTACE would benefit from a standardization in the reconstitution of the drug. In this study,
the comparison of the kinetics of distribution of the drug within the tumor micro-environment
is expected to allow for comparison of drug solvents.
This pilot study aims at evaluating the kinetics of distribution of the drug within the tumor
micro-environment, for the two main solvents used in reconstituting the drug, namely normal
saline and contrast media. The kinetics of distribution in the tumor will be evaluated
primarily through regular biopsy sampling, and secondary with confocal laser endomicroscopy.
| Status | Completed |
| Enrollment | 10 |
| Est. completion date | October 9, 2019 |
| Est. primary completion date | October 9, 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Adult (>18) - Informed consent - CHC Child-Pugh stage A or B, BCLC stage B - Referred for chemoembolization of a non-surgery-candidate CHC - Blood test results compatible with cTACE (INR = 1,5, ASAT/ALAT<5N, albumine>2,5g/dl) Exclusion Criteria: - Contraindication to cTACE, angiography, confocal laser endomicroscopy or liver biopsy Hyperthyroidism - Contraindication to the use of fluorescein, Ariblastine,Lipiodol, Visipaque, Gelita spon, Avitene - extra hepatic metastasis - Subcapsular or exophytic tumor impeding direct percutaneous access through healthy liver tissue - Waiting list for liver transplant - Complete portal venous thrombosis or flow inversion - Pregnancy or breast feeding - Protected major (Guardianship) - Patient in situation of exclusion (determined by a previous or ongoing study) - Subject incapacity to understand informed consent |
| Country | Name | City | State |
|---|---|---|---|
| France | University Hospital, Strasbourg, france | Strasbourg |
| Lead Sponsor | Collaborator |
|---|---|
| University Hospital, Strasbourg, France |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution | Biopsy samples of liver tumor tissue. Histological analysis will provide a quantification of the doxorubicin drug in tumor compartment. | T0: 1 min before cTACE drug injection star | |
| Primary | Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution | Biopsy samples of liver tumor tissue. Histological analysis will provide a quantification of the doxorubicin drug in tumor compartment. | T1 : 2 min after cTACE drug injection started | |
| Primary | Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution | Biopsy samples of liver tumor tissue. Histological analysis will provide a quantification of the doxorubicin drug in tumor compartment. | T2: 1 second after half of cTACE drug has been injected | |
| Primary | Histological analysis of biopsy samples for the evaluation of the kinetics of distribution of doxorubicine in tumor compartments depending on the solvent used for drug reconstitution | Biopsy samples of liver tumor tissue. Histological analysis will provide a quantification of the doxorubicin drug in tumor compartment. | T3: 1 min after cTACE drug injection is completed | |
| Secondary | In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution | Continuous image recording (videos) through the course of the cTACE drug injection, from 1 minute before drug injection starts to the time when cTACE drug injection is completed | 1 min before cTACE drug injection starts, | |
| Secondary | In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution | Continuous image recording (videos) through the course of the cTACE drug injection, from 1 minute before drug injection starts to the time when cTACE drug injection is completed | 2 min after cTACE drug injection started, | |
| Secondary | In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution | Continuous image recording (videos) through the course of the cTACE drug injection, from 1 minute before drug injection starts to the time when cTACE drug injection is completed | 1 second after half of cTACE drug has been injected, | |
| Secondary | In vivo evaluation of the kinetics of distribution of doxorubicine in tumoral tissue with confocal laser endomicroscopy, depending on the solvent used for drug reconstitution | Continuous image recording (videos) through the course of the cTACE drug injection, from 1 minute before drug injection starts to the time when cTACE drug injection is completed | 1 min after cTACE drug injection is completed, |